Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees

ISS recommended that Anavex shareholders vote for all six of the company’s director nominees at its September 24, 2026 annual meeting, concluding that dissident PVG "has not made a compelling case for change." ISS cited board actions including the former CEO’s removal, appointment of an interim CEO, planned hiring of permanent CEO/CFO/CMO leadership, and a board refresh that would leave half the board composed of new members. The endorsement supports Anavex’s incumbent slate in the proxy contest, though the outcome remains subject to shareholder voting.

Analysis

ISS support modestly improves the incumbent slate's probability of prevailing, but it does not underwrite AVXL's intrinsic value: the investable question remains whether a newly constituted leadership team can translate its reset into a credible regulatory and capital-allocation plan. A management transition at a clinical-stage biotech typically raises near-term cash-burn and execution uncertainty, particularly if key development, finance, and medical roles are still unfilled. Any post-meeting relief rally is therefore likely liquidity- and positioning-driven rather than a durable rerating absent a disclosed CEO hire, program prioritization, and quantified runway.

The second-order effect is that a weakened dissident outcome may remove a near-term governance catalyst that had supported the shares, while leaving legacy credibility issues unresolved. That can widen the valuation discount versus CNS-development peers because investors will require proof that the board can independently evaluate clinical/regulatory strategy rather than simply stabilize governance. The key 1-3 month catalyst is the annual-meeting result followed by executive appointments; the 6-18 month catalyst is independently verifiable regulatory engagement, trial execution, and financing terms.

Contrarian view: the market may be over-crediting ISS as an operational endorsement. Proxy advisers assess governance and slate quality, not probability-adjusted clinical value or financing risk. Conversely, if the vote is decisive and the board rapidly appoints experienced operators with a transparent cash runway, removal of the activist overhang could enable a sharper-than-expected rerating in a heavily sentiment-driven small-cap biotech.

No read-through exists for NDAQ beyond routine proxy-processing activity; this is not a material earnings or multiple catalyst.

Key Decisions for Investors

• Do not establish a directional AVXL position solely on the proxy recommendation; treat the September 24 vote as an event-risk date, not a fundamental catalyst.
• For existing AVXL longs, reduce into a pre-meeting relief move unless management provides a named permanent CEO/CFO/CMO, program milestones, and runway sufficient to avoid a discounted financing within 12 months.
• Set a post-vote watch trigger for AVXL: consider a tactical 1-3 month long only after leadership appointments and a financing/runway disclosure. Falsify on delayed appointments, incremental cash-burn guidance, or any regulatory update that weakens the development path.
• For event-driven books, monitor borrow cost, short interest, and the vote margin. A narrow incumbent win or meaningful dissent would preserve governance pressure and is more bearish than the headline; a decisive win plus credible executive hires is the only setup warranting covering a tactical short.